6 results about "CD43" patented technology

Compositions and methods that are useful for inducing phagocytosis of a cancer cell and / or increasing killing of a cancer cell (e.g., by an immune cell) by contacting the cancer cell with an antibody capable of selectively binding to a CD43 protein expressed on the surface of cancer cells. In various embodiments, the CD43 protein is not expressed on the surface of a healthy cell.

The application discloses a single-chain antibody targeting CD43, and constructs a fusion protein and immune cells expressing the same on the basis of the single-chain antibody, and further discloses the use of the single-chain antibody, the fusion protein or the immune cells in treating tumors or cancers. The CAR-T cell CAR-T-43 targeting CD43 has high safety and effectiveness.

The invention discloses a method for obtaining, activating and amplifying natural killer cells through iPSC differentiation induction, and relates to the technical field of stem cell biology, the method for obtaining, activating and amplifying natural killer cells through iPSC differentiation induction comprises the following steps: S1, preparing and inoculating iPSC cells; s2, differentiating the iPSC to a mesoderm; s3, the mesoderm cells are differentiated to CD34 + hematopoietic endothelial cells; s4, differentiating the CD43 < + > / CD45 < + > hematopoietic stem cells into the iNK cells; s5, maturation of the iNK cells; s6, activating and amplifying the iNK cells; in the step S1, cells are resuspended by using a fresh E8 complete culture medium and are inoculated into a porous culture plate; a plurality of induction culture media are used in the culture process; by adopting a porous culture plate and using an E8 complete culture medium to resuspend cells, efficient inoculation and primary culture of iPSC are realized, and the survival rate and amplification efficiency of cells are improved; the differentiation process of the iPSC towards the mesoderm, the hematopoietic endothelial cells and the CD34 + hematopoietic stem cells is optimized by using various induction culture media, and the differentiation efficiency is improved.

The present invention discloses universal cells and methods for their production. By inactivating major histocompatibility complex (MHC) class I and class II genes in cells and then overexpressing at least one of SLC35A1, GNE, CMAS, ST3Gal5, ST8SIA1, MUC1, APMAP, SMAGP, and CD43, the resulting human pluripotent stem cells or human cell lines can avoid attack by T cells and further avoid killing by NK cells and macrophages. At the same time, these low-immunogenic pluripotent stem cells retain their stemness and differentiation potential. [Figure 1] JPEG2026501446000009.jpg117169

Disclosed are therapeutic agents capable of trapping large proteins (e.g., CD45, CD148, and CD43) between the cell interface between transplanted cells and CD45-positive host effector cells (e.g., T cells, NK cells, B cells, or dendritic cells), as well as methods of their use and products made from such therapeutic agents. The therapeutic agents prevent or inhibit the formation of functional immune synapses, including physiological SMAC. They also result in sustained dephosphorylation of the signal transduction pathways.

The present invention relates to the field of tumor immunology. It provides a method for identifying mutation-related human CD8+ T cells, in particular, tumor-specific T cells of a human subject, comprising analyzing CD8+ T cells of the subject by analysing the expression of at least one marker selected from a first group consisting of CD82, CD194, CD244, CD28, CD62L and CD55, and preferably, a marker selected from a second group comprising CD11a or CD18 or CD43. A preferred marker for mutation-related CD8+ T cells is CD82, which may be analysed in combination, e.g., with CD11a. Without the need to identify any epitope to which T cells reacts, this method can advantageously be used to isolate the entire individual pool of mutation-related T cells, and, optionally, to identify the sequence of a mutation-related TCR, which allows for generation of transgenic T cells expressing the TCR. Compositions substantially comprising tumor-specific CD82hiCD8+ T cells and / or CD194hi, CD244−, CD28+, CD62L+ and / or CD55+ CD82hiCD8+ T cells can be used for treatment of a cancer patient, e.g., by adoptive T cell transfer. The method of the invention can also be used for diagnostic purposes to identify human mutation-related T cells or diagnosing a tumor disease or for testing responses of a cancer patient to an immune stimulatory therapy, preferably, a therapy with a checkpoint inhibitor.